Literature DB >> 21468601

Knockdown of STEAP4 inhibits insulin-stimulated glucose transport and GLUT4 translocation via attenuated phosphorylation of Akt, independent of the effects of EEA1.

Rui Cheng1, Jie Qiu, Xiao-Yu Zhou, Xiao-Hui Chen, Chun Zhu, Da-Ni Qin, Ji-Wu Wang, Yu-Hui Ni, Chen-Bo Ji, Xi-Rong Guo.   

Abstract

The aim of this study was to investigate whether the early endosome antigen 1 (EEA1) and/or PI3K pathway is involved in the molecular mechanisms underlying the effects of the six-transmembrane protein of prostate 4 (STEAP4; also called STAMP2 and TIARP) on the insulin sensitivity of human adipocytes. Our data demonstrated that siRNA-mediated STEAP4 deficiency significantly decreased insulin-stimulated glucose transport in mature human adipocytes by decreasing GLUT4 translocation to the plasma membrane through attenuated Akt phosphorylation. We further found that EEA1 may not be involved in the mechanisms underlying the effects of STEAP4 on insulin-stimulated glucose uptake and GLUT4 translocation, as indicated by the results that i) STEAP4 does not alter the effects of EEA1 on insulin-stimulated glucose uptake and GLUT4 translocation; ii) STEAP4 does not modify the expression of EEA1 protein; and iii) STEAP4 does not interact with EEA1 according to FRET analysis. In conclusion, this study revealed that the knockdown of STEAP4 inhibits insulin-stimulated glucose transport and GLUT4 translocation via the attenuated phosphorylation of Akt, independent of the effects of EEA1.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21468601     DOI: 10.3892/mmr.2011.443

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

Review 1.  STEAP4: its emerging role in metabolism and homeostasis of cellular iron and copper.

Authors:  Rachel T Scarl; C Martin Lawrence; Hannah M Gordon; Craig S Nunemaker
Journal:  J Endocrinol       Date:  2017-06-02       Impact factor: 4.286

2.  The crystal structure of six-transmembrane epithelial antigen of the prostate 4 (Steap4), a ferri/cuprireductase, suggests a novel interdomain flavin-binding site.

Authors:  George H Gauss; Mark D Kleven; Anoop K Sendamarai; Mark D Fleming; C Martin Lawrence
Journal:  J Biol Chem       Date:  2013-06-03       Impact factor: 5.157

Review 3.  STEAP4 and insulin resistance.

Authors:  Xiaoling Chen; Zhiqing Huang; Bo Zhou; Huan Wang; Gang Jia; Guangmang Liu; Hua Zhao
Journal:  Endocrine       Date:  2014-03-14       Impact factor: 3.633

4.  Utilisation of the STEAP protein family in a diagnostic setting may provide a more comprehensive prognosis of prostate cancer.

Authors:  Stephanie E A Burnell; Samantha Spencer-Harty; Suzie Howarth; Owen Bodger; Howard Kynaston; Claire Morgan; Shareen H Doak
Journal:  PLoS One       Date:  2019-08-08       Impact factor: 3.240

5.  The expression of STEAP4 in peripheral blood predicts the outcome of septic patients.

Authors:  Haiyan Jiang; Yansong Dong; Dajun Yan; Yao Wu; Yue Wang; Yuting Ren; Guomin Mao; Guiwen Liang; Wei Liu; Yang Zhou; Zhongwei Huang; Lei Qi
Journal:  Ann Transl Med       Date:  2021-10

6.  Genome-wide association study of meat quality traits in a White Duroc×Erhualian F2 intercross and Chinese Sutai pigs.

Authors:  Junwu Ma; Jie Yang; Lisheng Zhou; Zhiyan Zhang; Huanban Ma; Xianhua Xie; Feng Zhang; Xinwei Xiong; Leilei Cui; Hui Yang; Xianxian Liu; Yanyu Duan; Shijun Xiao; Huashui Ai; Jun Ren; Lusheng Huang
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

7.  Differential expression and function of stamp family proteins in adipocyte differentiation.

Authors:  Jørgen Sikkeland; Fahri Saatcioglu
Journal:  PLoS One       Date:  2013-07-10       Impact factor: 3.240

8.  STAMP2 is required for human adipose-derived stem cell differentiation and adipocyte-facilitated prostate cancer growth in vivo.

Authors:  Torstein Lindstad; Su Qu; Jørgen Sikkeland; Yang Jin; Alexandr Kristian; Gunhild M Mælandsmo; Philippe Collas; Fahri Saatcioglu
Journal:  Oncotarget       Date:  2016-08-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.